DINOPROST

Small molecule targets PTGFR via activation

Investigated by: Canadian Anesthesiologists' Society · Samuel Lunenfeld Research Institute, Mount Sinai Hospital · University of Toronto

2009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
—	NCT01689311	Mar 2009 → Aug 2011	—	Samuel Lunenfeld Research Institute, Mount Sinai Hospital	Completed	No outcome recorded

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
—	NCT01327118 Comparator	Sep → Dec 2010	headache disorder	Danish Headache Center	Completed	No outcome recorded

Every value below carries the sentence it was read from. 4 sources stand behind the page.

Field	Value	Cited text
Known as	DINOPROST	ChEMBL registry synonym — accepted as the source's own label CHEMBL815 ↗
Known as	Lutalyse	ChEMBL registry synonym — accepted as the source's own label CHEMBL815 ↗
Known as	Pgf2.alpha.	ChEMBL registry synonym — accepted as the source's own label CHEMBL815 ↗
Known as	Pgf2a	ChEMBL registry synonym — accepted as the source's own label CHEMBL815 ↗
Known as	PGF2α	“PURPOSE: To compare the in vitro contractile responses to oxytocin, ergonovine, prostaglandin F2 alpha (PGF2α), and misoprostol in isolated myometrium from” PMID 24906304 ↗ Jun 2014
Known as	Prosmon	ChEMBL registry synonym — accepted as the source's own label CHEMBL815 ↗
Known as	prostaglandin F2 alpha	“PURPOSE: To compare the in vitro contractile responses to oxytocin, ergonovine, prostaglandin F2 alpha (PGF2α), and misoprostol in isolated myometrium from” PMID 24906304 ↗ Jun 2014 2 NCT01689311 ↗ NCT01327118 ↗
Known as	U-14,583	ChEMBL registry synonym — accepted as the source's own label CHEMBL815 ↗
Action	Activate	“Prostanoid FP receptor agonist” CHEMBL815 ↗
Modality	Small molecule	— CHEMBL815 ↗
Route	Intravenous	“intravenous injection” NCT01327118 ↗
Target	PTGFR	“Prostanoid FP receptor agonist” CHEMBL815 ↗